Immunomodulating Treatment of Multiple Sclerosis — the Tasks and Role of a Neurological Nurse
DOI:
https://doi.org/10.15225/PNN.2018.7.4.5Keywords
multiple sclerosis, immunomodulating drugs, nursing careAbstract
Multiple Sclerosis (SM) is the most common chronic inflammatory autoimmune demyelinating disease affecting the central nervous system. It affects mainly young people, aged 20–40.The onset of the disease usually takes the form or bouts followed by periods of remission. Immunomodulating treatment is a long-term therapy whose aim is to inhibit the occurrence of relapses and, in the long term-delay development of disability in a patient. The effectiveness of this treatment depends, among others, on the degree of preparation of the patient and their following the rules of the therapy. Most of the medication applied is administered by the patient at home as an injection or in the form of oral therapy. Nowadays two drugs are administered in hospitals. Since the very beginning of the treatment the patient and their family is provided with nursing care whose scope depends on the drug administered and on the condition of a patient. The procedures undertaken by the nurse include: educating the patient and their family in the preparation and administration of a drug, coping with adverse effects, monitoring the neurological and emotional condition of a patient and providing support during all treatment period. (JNNN 2018;7(4):160–165)
References
Compston A., Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
Pugliatti M., Rosati G., Carton H. et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13(7):700–722.
Selmaj K. Stwardnienie rozsiane. Wyd. Termedia, Poznań 2006.
Losy J., Selmaj K., Neuroimmunologia kliniczna. Wyd. Czelej, Lublin 2007.
Losy J. Kiedy włączać leczenie II linii w stwardnieniu rozsianym? Aktual Neurol. 2015;15(3):124–129.
Losy J., Bartosik-Psujek H., Członkowska A. i wsp. Leczenie stwardnienia rozsianego. Zalecenia Polskiego Towarzystwa Neurologicznego. Pol Prz Neurol. 2016;12(2):80–95.
Załącznik B.29. Leczenie stwardnienia rozsianego (ICD-10 G 35). Retrieved June 10, 2018, from http://onkologia-online.pl/upload/obwieszczenie/2017.10.25/b/b.29.pdf
Dörr J., Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17(6):354.
Filippi M., Rocca M.A., Camesasca F. et al. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011;76(14):1222–1228.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655–661.
Podlecka-Piętowska A. Leczenie modyfikujące przebieg choroby w stwardnieniu rozsianym. Neurologia po Dyplomie. 2008;3(5):11–18.
Wilkiewicz M., Smelkowska A., Jaracz K., Grabowska-Fudala B., Pniewska J. Opieka pielęgniarska nad pacjentem ze stwardnieniem rozsianym w trakcie leczenia immunomodulacyjnego lekami pierwszego rzutu. Pielęg Neurol Neurochir. 2013;2(5):223–227.
Wilkiewicz M., Smelkowska A., Grabowska-Fudala B., Jaracz K. Course of Care of a Multiple Sclerosis Patient in the Context of Pharmacotherapy. J Neurol Neurosurg Nurs. 2015;4(3):130–137.
Grabowska-Fudala B. Rola pielęgniarki w leczeniu stwardnienia rozsianego. Pielęg Neurol Neurochir. 2012;1(1):29–34.
Wilkiewicz M. Diagnoza pielęgniarska i plan opieki nad chorym ze stwardnieniem rozsianym. W: Jaracz K., Kozubski W. (Red.), Pielęgniarstwo neurologiczne, Wyd. Lekarskie PZWL, Warszawa 2008:257–264.
Johnson K.P., Brooks B.R., Cohen J.A. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50(3):701–708.
Ford C.C., Johnson K.P., Lisak R.P. et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12(3):309–320.
Gold R., Giovannoni G., Phillips J.T. et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler. 2015;21(1):57–66.
European Medicines Agency, Science Medicines Health. Retrieved June 10, 2018, from https://www.ema.europa.eu/medicines/human/EPAR/tecfidera
Stępień A. Dimethyl fumarate — a new drug in multiple sclerosis therapy. Aktual Neurol. 2015;15(3):139–143.
Aneks I. Charakterystyka produktu leczniczego. Aubagio. Retrieved June 15, 2018, from https://www.google.pl/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=2ahUKEwiC1Mygv4_eAhVllIsKHb3lDLgQFjAAegQIBxAC&url=https%3A%2F%2Fec.europa.eu%2Fhealth%2Fdocuments%2Fcommunity-register%2F2015%2F20151216133467%2Fanx_133467_pl.pdf&usg=AOvVaw3tAfhQuFq_97XEQzQ1bNAE
Confavreux C., O’Connor P., Comi G. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256.
Polman C.H., O’Connor P.W., Havrdova E. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
Niino M., Bodner C., Simard M.L. et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006;59(5):748–754.
O’Leary S., Beavin J., Bishop C., Capolino L., Greinel E., Hudson E. Practical Guidelines for Administering Natalizumab: A Nursing Perspective. Int J MS Care. 2007;9:1–8.
Fernández O. Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(2):69–79.
Chun J., Hartung H.P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101.
Harrison K. Fingolimod for multiple sclerosis: a review for the specialist nurse. Br J Nurs. 2014;23(11):582–589.
Aneks I. Charakterystyka produktu leczniczego. Gilenya. Retrieved June 16, 2018, from http://ec.europa.eu/health/documents/community-register/2018/20180423140861/anx_140861_pl.pdf
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 639
Number of citations: 0